ENANTA PHARMACEUTICALS INC 8-K

What Happened

• Enanta Pharmaceuticals, Inc. announced its financial results for the fiscal quarter ended March 31, 2026 in a press release and furnished that release to the SEC on May 11, 2026. The press release reporting the company’s quarterly results is included as Exhibit 99.1 to the Form 8-K. The report was signed by President and CEO Jay R. Luly, Ph.D.

Key Details

• Filing date: May 11, 2026 (Form 8-K filed with the SEC).
• Reporting period: fiscal quarter ended March 31, 2026.
• Disclosure method: press release furnished as Exhibit 99.1 to the 8-K.
• Signature: Form 8-K signed by Jay R. Luly, Ph.D., President and Chief Executive Officer.

Why It Matters

• This 8-K informs investors that Enanta has publicly reported its latest quarterly earnings and related financial condition; the specific financial figures and any management commentary are in the attached press release (Exhibit 99.1). Quarterly results can affect expectations for revenue, profitability, and the company’s near-term outlook—investors should review the press release for the detailed numbers and any guidance or operational updates.